Views & Analysis Nine for 2019: how did we do on our predictions, and what do... Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead.
Views & Analysis Nine for 2019: Opportunities for pharma In the last Nine for 2019 article, we reflected on the major challenges that are sha
Views & Analysis Nine for 2019: Challenges impacting pharma As we move close to 2019’s halfway point, it’s time to reflect on the issues that are shaping the pharmaceutical industry for this year and beyond.
News Gene therapy firm Kate Tx snapped up by Novartis for $1.1bn Novartis buys gene therapy specialist Kate Therapeutics for $1.1 billion, adding an early-stage rival to Sarepta's muscular dystrophy therapy Elevidys
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
